Drugs / PRX-03140
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00693004 | May 2008 → Jan 2010 | Alzheimer disease | Epix Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00672945 | Apr 2008 → Jan 2010 | Alzheimer disease | Epix Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00384423 | Oct 2006 → Oct 2007 | Alzheimer disease | Epix Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01492699 | Jun 2012 → Jun 2013 | post-traumatic stress disorder | Alachua Government Services, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRX-03140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00384423 ↗ |
| Action | Activate | “Serotonin 4 (5-HT4) receptor partial agonist” CHEMBL3306918 ↗ |
| Modality | Small molecule | — CHEMBL3306918 ↗ |
| Route | Oral | “PRX-03140 administered orally once daily for 14 days” NCT00384423 ↗ |
| Target | HTR4 | “Serotonin 4 (5-HT4) receptor partial agonist” CHEMBL3306918 ↗ |